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Abstract
Background: Some individuals with functional gastrointestinal disorders (FGID) suffer long-lasting
symptoms without ever consulting their doctors. Our aim was to study co-morbidity and lifestyle
differences among consulters and non-consulters with persistent FGID and controls in a defined
adult population.
Methods: A random sample of the general adult Swedish population was obtained by a postal
questionnaire. The Abdominal Symptom Questionnaire (ASQ) was used to measure GI
symptomatology and grade of GI symptom severity and the Complaint Score Questionnaire (CSQ)
was used to measure general symptoms. Subjects were then grouped for study by their
symptomatic profiles. Subjects with long-standing FGID (n = 141) and subjects strictly free from
gastrointestinal (GI) symptoms (n = 97) were invited to attend their local health centers for further
assessment.
Results: Subjects with FGID have a higher risk of psychological illness [OR 8.4, CI95(4.0–17.5)]
than somatic illness [OR 2.8, CI95(1.3–5.7)] or ache and fatigue symptoms [OR 4.3, CI95(2.1–8.7)].
Subjects with psychological illness have a higher risk of severe GI symptoms than controls;
moreover they have a greater chance of being consulters. Patients with FGID have more severe GI
symptoms than non-patients.
Conclusion: There is a strong relation between extra-intestinal, mental and somatic complaints
and FGID in both patients and non-patients. Psychological illness increases the chance of
concomitantly having more severe GI symptoms, which also enhance consultation behaviour.
Background
Gastrointestinal (GI) symptoms are common and are
reported within three months by almost every other adult
in Western countries (UK, Sweden, USA, Australia) [1-5].
(The abbreviations used in this manuscript are explained
in the Additional File.) The most common symptoms are
gastroesophageal reflux symptoms/disease (GERS) and
dyspepsia originating from the upper GI tract, and Irrita-
ble Bowel Syndrome (IBS) from the lower GI tract. Preva-
lence rates are reported to be 25% for both GERS and
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dyspepsia and about 12% for IBS [6]. Although intermit-
tent, these disorders may linger in many sufferers [2,7].
The total cost of dyspepsia to society, with and without
peptic ulcer disease, GERS and IBS, is considerable [8,9].
Thus, these disorders constitute a major public health
problem.
Dyspepsia without peptic ulcer disease (PUD) (or any
other organic GI disease) is called functional dyspepsia
[10]. In a Swedish population-based upper endoscope
study, the prevalence of dyspepsia was 38% and the prev-
alence of PUD 4%, with about a quarter of the PUD sub-
jects having no GI symptoms [48]. Thus, the vast majority
of those reporting dyspepsia in the population can be
expected to have functional dyspepsia. IBS is a functional
gastrointestinal disorder [11]. Although functional dys-
pepsia and IBS are considered separate disorders [10,12],
many subjects report concomitant symptoms thought to
originate from both the upper and the lower the GI tract
[1,13]. Also, sufferers may experience a change in pre-
dominant symptom profile over time between dyspepsia
and IBS, but much less towards GERS [2]. This means that
dyspepsia and IBS sufferers probably have common
aspects of both pathophysiology and health care seeking
behavior. Furthermore GERS, in a majority of cases, has a
proven (non-functional) acid-related etiology [11].
Accordingly, it seems reasonable to exclude subjects with
only GERS symptoms from the functional definition and
to investigate the burden on society of functional dyspep-
sia and IBS taken together. We thus label these conditions
as functional gastrointestinal disorders or FGID.
A minority of subjects with FGID (5–20%) are reported to
visit a doctor quarterly for their complaints [14,15]. On
the other hand, up to half of those with FGID never see a
doctor despite prolonged symptoms [14,16]. For IBS, the
proportion is even higher, up to 80 % [14]. Thus, GI
patient-based data will not cover all aspects of morbidity.
Moreover, it has been reported previously that most
patients' sick leave is due to disorders other than their
abdominal complaints. Only 23% of those subjects with
abdominal pain who were on sick leave stated that
abdominal pain was the cause of their absenteeism [17].
There are prior cross-sectional population-based point
prevalence studies on GI co-morbidity [18-20]. However,
there is a lack of knowledge of the co-morbidity of sub-
jects with proven chronic/long lasting/persistent FGID
and its impact on health care seeking behaviour due to GI
symptoms. The aim of this study was to compare the co-
morbidity and its relation to health care seeking behav-
iour among non-patients with persistent FGID with those
who are persistently GI symptom free, in a randomly-
selected adult Swedish population.
Methods
Setting
In January 1995 there were a total of 21,545 Swedish citi-
zens in the Östhammar community, 14,932 of whom
were born between 1909 and 1974. Data from three prior
studies[2], which included random samples of the Öst-
hammar population, were used to provide symptom-free
controls in the current study. We called this new study the
Gastrointestinal Consult Study (GiCon). A sample was
drawn from the National Swedish Population Registry
1995, now involving all Swedish citizens born between
1909 to 1974 and thus 20 to 87 years of age, born on day
3, 12 or 24 of each month (n = 1537), i.e. using the same
date of birth criteria as in previous studies on the same
population in 1988 and 1989. Thus, we increased the
upper age limit to 87 years in order to include all prior
participants. As a consequence of the sampling strategy,
all subjects younger than 27 years of age were included for
the first time (n = 86). Most the participants were now
being approached for the third time. Of the 1537 subjects
in the study base (see Figure 1), 105 were excluded due to
having declined further participation in the 1988 study
and 4 were excluded due to unidentified ID. Thus, 1428
subjects were still eligible. They were sent a validated
postal questionnaire, called "The Abdominal Symptom
Questionnaire" (ASQ) [21], described below. Two
reminders were sent out when necessary. Drop-out rea-
sons are shown in Figure 1, together with the mean age
and sex distributions of the 911 responders who consti-
tuted the population sample of the current GiCon study.
Formation of the study groups and symptom classification
All 911 responders in the population sample were classi-
fied according to their response in the ASQ (see Figure 1)
as having either Functional Gastrointestinal Disorder
(FGID, n = 244), i.e. functional dyspepsia or irritable
bowel syndrome, or being Strictly Symptom Free (SSF, n
= 219). Moreover, subjects reporting minor symptoms
that did not fulfil the criteria for dyspepsia or irritable
bowel syndrome, or reporting isolated symptoms of gas-
troesophageal reflux symptoms (GERS, n = 271), were
excluded. Subjects who were free from abdominal symp-
toms in this 1995 survey but had reported symptoms in
the previous studies (1988–1989) were labelled as Prior
Symptomatic (n = 177) and were also excluded.
The FGID and SSF sample groups (n = 244 + 219 = 463)
were then invited by post to participate in the current
investigation and to visit one of the six local health cen-
tres. Subjects who did not respond to the first letter were
sent a reminder, and non-responders to the second letter
were finally contacted by phone. In total, 187 (77%) with
FGID and 156 (71%) with SSF accepted the invitation.
There were 117 (57 FGID, 60 SSF) subjects with incom-
plete (n = 12) or no (n = 105) response. At the healthBMC Medicine 2005, 3:8 http://www.biomedcentral.com/1741-7015/3/8
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Sampling procedure of the Gastrointestinal Consult Study (GiCon study) Figure 1
Sampling procedure of the Gastrointestinal Consult Study (GiCon study). Sampling procedure of the Gastrointesti-
nal Consult Study (GiCon study) with relation to the prior study of 1995.BMC Medicine 2005, 3:8 http://www.biomedcentral.com/1741-7015/3/8
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centres, the participants filled in an ASQ and a Complaint
Score Questionnaire (CSQ), as described below, and the
height and weight of each was measured. The time period
between the original 1995 ASQ and the second ASQ sur-
vey in 1996 ranged from 7 to 15 months. Of the FGID
group of 187 subjects, 8 subjects who now reported no
symptoms and 38 with minor symptoms were excluded;
and out of the 156 SSF, 13 who now reported FGID and
46 with minor symptoms were also excluded. Thus, data
from 141 FGID subjects (mean age 45.7 y, 34% men) and
97 SSF subjects (mean age 52.4 y, 48% men) remained in
the analysis. The sampling procedure for retrospective
data – twice over one year for those with, and up to four
times over eight years for those without, GI symptoms –
assured persistent symptomatic status.
Questionnaires
The abdominal symptom questionnaire
The Abdominal Symptom Questionnaire (ASQ) has been
validated previously and found to be reliable and repro-
ducible [2,13,22]. In the questionnaire, subjects were
asked if they had been troubled (Yes/No) by any of the 29
listed general gastrointestinal symptoms over the previous
three months. They were also asked if they had been trou-
bled by any of 11 listed descriptors of abdominal pain and
where the symptom was located (upper, centre or lower
abdominal, right and left flank, as shown in Figure 2). A
similar ASQ was used for the postal survey and the surgery
visit, with the latter extended to include a symptom sever-
ity Likert scale graded from zero to seven for each symp-
tom asked for. In the analysis, the data were pooled into a
three-grade scale (1, 1–4, 5–7)
GI symptoms, pain modalities and location Figure 2
GI symptoms, pain modalities and location. The symptoms inquired are shown in Part 1, and the pain and discomfort 
modalities with the master sketch for indicating their abdominal location in Part 2. The asterisks are explained in the text. 
Swedish laymen terms were used in the questionnaire. The master sketch shows the eligible pain locations.BMC Medicine 2005, 3:8 http://www.biomedcentral.com/1741-7015/3/8
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Definitions of symptoms from the ASQ
(See Figure 2) [23].
Dyspepsia was defined as one or more of the symptoms
(reflux episodes, heartburn, retrosternal pain, nausea,
vomiting, early satiety, uncomfortable feeling of fullness
after meals, abdominal distension), and one or more of
the pain modalities (burning sensation, aching, pain, ten-
derness, sinking feeling, "butterflies", cramp, twinge,
stitch, colic, gripes) with any abdominal location except
the lower part, but no concomitant IBS.
Irritable Bowel Syndrome (IBS) was defined as one or more
of the symptoms (abdominal distension, abdominal dis-
comfort or pain on defecation, abdominal discomfort or
pain relieved by defecation, feeling of incomplete defeca-
tion, mucous stools) and one or more of the symptoms
(diarrhea, constipation, alternating diarrhea and consti-
pation) together with one or more of the pain modalities
(burning sensation, aching, pain, tenderness, sinking feel-
ing, "butterflies", cramp, twinge, stitch, colic, gripes), with
any location.
When using these definitions of dyspepsia and IBS,
responders with only reflux symptoms, i.e. heartburn
and/or retrosternal pain but no abdominal pain or dis-
comfort, were classified as having GERS and not dyspep-
sia, while those with such symptoms and abdominal pain
or discomfort fell into the dyspepsia group. Also, IBS, as
defined below, was given priority over dyspepsia. Thus,
concomitant occurrence of both led to a diagnosis of IBS.
This definition is in accordance with published guidelines
[24].
Functional Gastrointestinal Disorder, FGID
FGID was defined as either dyspepsia or IBS.
Minor symptoms refer to symptoms not fulfilling the crite-
ria of dyspepsia or IBS. By definition, those with GERS
were included in this group
"Strictly Symptom Free" (SSF) is defined as having no
reported symptoms at all in the Abdominal Symptom
Questionnaire in the 1995 survey, and subjects stating
that they had not even been troubled previously with
abdominal symptoms. Those subjects who had partici-
pated in the two former surveys in 1988 and 1989 (n =
265) should also have reported no symptoms in each of
those two investigations.
"Prior symptomatics" were those with no symptoms in the
1995 survey but with GI symptoms reported in the prior
studies of 1988 and 1989.
The complaint score questionnaire
The Complaint Score Questionnaire contains 30 ques-
tions, as shown in Figure 3, indicating the presence or
absence of 30 different symptoms [25]. The questions are
dichotomous and can be categorized into six domains:
abdominal/urinary, ache/fatigue, muscular-skeletal,
nutritional, cardio-vascular and depressive.
Other questions
The participants were asked to state their coffee, alcohol
and tobacco consumption, and whether they had ever had
peptic ulcer disease or had ever consulted a doctor for GI
complaints. Also, the past three months of general pain
and all GI medication were indicated. Educational back-
ground was registered at five levels (elementary, compre-
hensive, secondary, upper secondary, university) and
medical knowledge was evaluated by means of a self-
explanatory questionnaire (see Additional File). The
answers were scored with a sum of 0–15.
Statistical power and analysis
One hundred and twenty three subjects were required (in
each the FGID and SSF groups) in order to have a 90%
power at the P < 0.05 level to detect a 20% absolute differ-
ence in exposure variables. This assumed a 24% preva-
lence of FGID in the population, equal numbers of
subjects in the FGID and SSF groups, 15 and 20% absolute
difference in the exposure variables within the two steps
of the study, 75% response rate on the ASQ, and 25%
exclusion from each group in the last step. The variables
analysed are presented in the Additional File. Univariate
analyses were performed using Student's t-test, Wilcoxon's
ranksum test (Mann Whitney) and Pearson's chi-2 test.
Multivariate analysis with FGID as the dependent variable
was performed using a logistic regression, and with dys-
peptic severity as the dependent variable with the ordinal
logistic regression technique. Age and BMI were linear to
outcome and were thus handled as continuous variables.
To test the symptoms in the CSQ, we made an age and sex
adjusted logistic regression model for each symptom and
accepted a P value less than 0.05/(number of symptoms)
= 0.05/30 ≈  0.0016 as significant. The explanatory varia-
bles were evaluated by a logistic regression in a sex and age
adjusted model.
The association between each potential determinant
obtained from the questionnaires and the presence of
FGID was quantified by using odds ratios and 95% confi-
dence intervals. All exposure variables with P < 0.25 were
then entered together in a multivariate logistic regression
model to evaluate which was independently associated
with the presence of FGID. A factor analysis was per-
formed using all 30 complaints and factors with eigenval-
ues greater than 1.3. Four factors were obtained by a
principal components analysis with varimax rotation. TheBMC Medicine 2005, 3:8 http://www.biomedcentral.com/1741-7015/3/8
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30 variables were dichotomized with the highest 1/3
given the value 1 and the rest the value 0. A logistic regres-
sion was performed with the four factors age and sex
adjusted, and factors with p > 0.05 were excluded. To test
whether the model fitted the data, a Pearson goodness-of-
fit test with p values greater than 0.05 was performed.
When the number of covariates approximated the number
of observations, the Hosmer-Lemeshow test was per-
formed to determine whether the model fitted the data.
For the ordinal logistic model, comparison with a multi-
nomial model made an approximate fit test. No interac-
tions were found between the variables in the main
model. Ninety five per cent confidence intervals (CI) were
computed using parametric methods. A p-value of 0.05 or
less was generally regarded as statistically significant. All
tests were two-tailed and the statistical package Stata 8 was
used for analysis [27].
Ethics
This study was approved by the Ethics Committee of the
Medical Faculty, Uppsala University, June 5th 1996.
Results
Representativeness of study sample
In order to investigate the effect of the drop-outs during
the sampling procedure, the mean ages, sex ratios and
education levels in the corresponding FGID and SSF
groups were analysed as shown in Table 1, for the samples
from 1988, 1995 and 1996 (see Table 1) [13]. There were
no significant differences in any of these aspects (see Table
1).
Study group characteristics
As shown in Table 2, there were more females among those
with FGID. However, there were no intergroup differences in
education, medical knowledge, BMI, intake of coffee, alcohol
and smoking. The age difference was irrelevant, as those with
SSF had been largely excluded due to prior study results. Dis-
ease-related variables were significantly different between the
study groups. These variables were introduced to further model-
ling, as shown below. The variables 'intake of GI medicine' and
'previous PUD' were not included due to sparse data.
Proportion of subjects with FGID and with SSF reporting complaints during the previous three months in the CSQ Figure 3
Proportion of subjects with FGID and with SSF reporting complaints during the previous three months in the 
CSQ. Proportions (0–1.0) of subjects with FGID and with SSF (n = 238) reporting complaints during the previous three 
months in the Complaint Score Questionnaire (CSQ). There were significance differences *(p < 0.0016) on an age and sex 
adjusted logistic regression for all variables except coughing (ns) and excessive weight (ns).BMC Medicine 2005, 3:8 http://www.biomedcentral.com/1741-7015/3/8
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CSQ and FGID vs. SSF
The results from the 30 CSQ complaints for the FGID and
SSF study groups are presented in Figure 3. Those with
persistent FGID scored statistically higher on all variables
except difficulties in passing urine, excessive weight,
coughing and impaired hearing.
Risk modelling
Risks of reported CSQ complaints for FGID vs. SSF,
expressed as age and sex adjusted OR, are presented in
Table 3. GI complaints (abdominal pain, nausea, diarrhea
and constipation) were excluded as we aimed to analyze
the co-morbidity with GI symptoms. The OR was signifi-
cant for all except four complaints. After adjusting for
alcohol and pain and GI drug intake (Table 3), 20
complaints remained significant. A factor analysis was
performed including the 26 non-GI complaints. After a
varimax rotation of the four factors with eigenvalues > 1.3,
we found four factors representing psychological illness,
somatic illness, ache/fatigue and one "miscellaneous"
(Table 3). Each factor was then introduced in a logistic
regression model adjusted for sex and age (Table 3), and
the "miscellaneous" factor was shown to be non-signifi-
cant. In the last sequential analysis, the three factors that
remained significant in the prior analysis were introduced
Table 1: Comparison between previous population studies in Östhammar, Sweden. Age, sex and education level at different stages of 
the sampling process. From the first population sample in 1988 to the present study 1996. ns = p > 0.05.
Group (G) Sample Year n Age years mean (SD) Sex % males Education median level (range)
1 First population sample 1988 1156 48.9 (16.0) 50.4 3 (1–4)*
2 Eligible sample 1995 1428 49.9 (17.2) 49.9 3 (1–4)**
3 Population sample 1995 911 49.2 (16.46) 47.0 3 (1–4)
4 Sample group FGID 1995 244 45.5 (15.3) 36.1 3 (2–4)
5 Sample Group SSF 1995 219 51.7 (17.6) 51.6 3 (1–4)
6 Study Group FGID 1996 141 45.7 (14.3) 34.0 3 (2–4)
7 Study Group SSF 1996 97 52.4 (15.3) 48.0 3 (1–4)
G2 vs G3 ns ns
G2 vs G3 ns ns ns
G4 vs G6 ns ns ns
G5 vs G7 ns ns ns
*responders = 1156 **responders n = 1384
Table 2: Comparison between explanatory variables for subjects with FGID and SSF. Comparison between explanatory variables for 
subjects with FGID and SSF adjusted for sex and age. Ordinal variables are presented as median (range), dichotomous variables as 
proportion %, and continuous variables as mean (SD).
Variable FGID
n = 141
SSF
n = 97
P
AGE 45.7 (14) 52.4 (15) not relevant
SEX (female %) 66 53 0.026 ***
BMI 26.3 (4.7) 26.2 (4.2) Ns *
Education 3 (2–4) 3 (1–4) Ns **
Medical knowledge 10 (4–15) 11 (5–15) Ns **
GI sympt severity 4 (3–5) 0 (0–0) <0.0005 **
GI Consultation (ever) 72% 8% <0.0005 ***
Pain medicine (3 month) 77% 34% <0.0005 ***
GI medicine (3 month) 32% 1% <0.0005 ***
Previous PUD (ever) 12% 1% 0.006 ***
Coffee 2 (2–3) 2 (2–3) Ns **
Alcohol 4 (3–4) 3 (2–4) Ns **
Smoking 1 (1–2) 1 (1–2) Ns **
* = Student's t-test ** = Mann-Whitney test *** = Pearson Chi-2 testBMC Medicine 2005, 3:8 http://www.biomedcentral.com/1741-7015/3/8
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together into a main effect model, adjusted for age and
sex. The OR for these factors remained significant, as
shown in Table 3.
Consulters versus non consulters
Consulters and non-consulters among those with persist-
ent FGID were compared regarding their complaints, as
reported in the CSQ. The proportion (0–1.0) per
complaint is shown in Figure 4. There were no statistically
significant differences between the consulters and non-
consulters for any of the complaints (adjusted for age and
sex, p > 0.0016).
ASQ symptom severity and consulting behaviour vs CSQ 
factors
From the ASQ, the mean grades of GI symptom severity
for affirmative symptoms were analyzed against the three
final CSQ factors from Table 3 (psychological illness,
somatic illness, ache/fatigue) and for age, sex and consult-
ing behaviour, as shown in Table 4. The analysis showed
an obviously higher risk of increased GI symptom severity
for consulters (OR 12.3) and for psychological illness (OR
4.5), while somatic illness and ache/fatigue had a low risk,
with the 95% CI close to 1.0. From the ASQ, consulting
behaviour was analyzed for the CSQ factors psychological
illness, abdominal illness, age and sex (see Table 5). The
analysis showed a greater chance of being a consulter for
abdominal illness (OR 2.0) and psychological illness (OR
2.2).
Table 3: Odds ratios of FGID/SSF for complaints in the Complaints Score Questionnaire (CSQ). Odds ratios (OR, with 95% confidence 
intervals (CI)) of FGID/SSF (n = 238) for complaints elicited by the CSQ. Logistic regression is presented in different models. A factor 
analysis extracted four factors: A = psychological illness factor, B = somatic illness factor, C = miscellaneous factor, D = ache/fatigue 
factor. These were used in the modelling in the right two columns.
I II III IV V
Symptom OR (CI) by Models 
adjusted for sex 
and age
OR (CI) by Models 
adjusted for sex, 
age, alcohol, pain 
tablets, GI-tablets
FACTOR OR (CI) by Models adjusted 
for sex and age
OR (CI) by a main effect model 
adjusted for sex and age
SSF (all variables) 1 (Reference) 1 (Reference)
FGID
Cries easily 6.7 (2.3–19.9) 9.8 (2.0–47) A 8.0 (4.1–15.8) 1) Psychological illness 8.4 (4.0–17.5) 1) Psychological illness
Sleeping disturbance 6.2 (2.7–14.0) 3.2 (1.3–8) A
General fatigue 14.5 (7.4–28.7) 12.6 (5.3–30) A, D
Irritability 8.8 (4.1–17.8) 5.6 (2.3 – 13.7) A, D
Nervousness 18.4 (4.2–80.3) 14.3 (2.8 – 72) A
Impaired concentration 19.0 (5.7–63.8) 15.3 (4.0 – 58) A
Difficulty to relax 15.7 (6.0–41.5) 10.9 (3.7–32) A
Restlessness 40.0 (9.4–170) 32.2 (6.7–154) A
Depression 8.6 (4.1–18) 4.7 (2.0 – 11) A
Exhaustion 12.7 (4.4–37) 9.1 (2.7–30) A
Chest pain 40.0 (5.3–300) B 3.7 (2.0–7.1) 1) Somaticillness 2.8 (1.3–5.7) 1) Somaticillness
Pain in the joints 6.2 (2.8–13.6) 7.5 (2.6–21) B
Pain in the legs 4.4 (2.2–8.9) 3.8 (1.6–9.3) B
Overweight 2.0 (1.0–4.0) 1.4 (0.6–3.6) B
Breathlessness 8.9 (3.2–25) 12.1 (3.3–45) B
Dizziness 10.1 (4.2–24) 11.4 (3.8–34) B
Impaired hearing 3.0 (1.3–6.8) 3.1 (1.0–9.5) B
Eye problem 4.2 (1.9–9.1) 3.4 (1.3–9.0) B
Loss of weight - - C 1.7 (0.9–3.0) 1) Miscellaneous
Bad appetite - - C
Feeling cold 7.3 (3.1–17) 7.0 (2.6–19) C
Difficulty in passing urine 9.6 (2.0–47) 9.1 (1.4–59) C
Back ache 4.4 (2.4–8.2) 2.0 (0.9–4.3) D 2.9 (1.6–5.2) 1) Ache/fatigue 4.3 (2.1–8.7) 1) Ache/fatigue
Headache 6.3 (3.4–12) 4.1 (1.9 – 9.1) D
Sweating 3.6 (1.7 – 7.4) 3.3 (1.3 – 8.5)
Coughing 2.0 (0.98–4.2) 1.7 (0.6–4.4)
1) Reference group (OR = 1) is those coded 0 in each factorBMC Medicine 2005, 3:8 http://www.biomedcentral.com/1741-7015/3/8
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Discussion
This study shows that among subjects with longstanding
FGID, there is a remarkably high prevalence of psycholog-
ical illness and also of non-GI somatic complaints. These
are present regardless of whether the subjects have con-
sulted their doctor about their GI problems, and are more
severe in subjects with persistent FGID. Although FGID
was more common in women, the consultation rates in
sufferers were similar for males and females and were not
age-related. Only about a quarter of the sufferers had
never consulted their doctor.
We consider that our findings can be generalized to the
whole population, as the study groups were sampled from
a well-defined and thoroughly investigated population,
most of whom had participated in prior studies [28,29].
The original study base was formed in 1988 from the
Swedish National Population register, which guarantees
complete coverage of all citizens. There were no differ-
ences in age, gender or education level between the study
Proportion of complaints from the Complaint Score Questionnaire among those with FGID, divided into Consulters and Non- Consulters Figure 4
Proportion of complaints from the Complaint Score Questionnaire among those with FGID, divided into Con-
sulters and Non-Consulters. Proportion (0–1.0) of complaints from the Complaint Score Questionnaire (CSQ) among 
those with FGID, divided into Consulters and Non-Consulters (n = 141). None of the variables showed a significant difference 
between Consulters and Non-Consulters for P values less than 0.0016, tested by a sex and age adjusted logistic regression.
Table 4: Odds ratios of graded GI symptom severities in the 
ASQ for consulting, psychological illness, somatic illness and 
ache/fatigue factors. Odds ratios (OR, with 95% confidence 
intervals (CI)) of graded (0,1,2) GI symptom severity in the ASQ 
for consulting, psychological illness, somatic illness and ache/
fatigue factors, age and sex, for both FGID and SSF (n = 232). 
Ordinal logistic regression.
Variable OR (CI)
Psychological illness low 1
high 4.5(2.4–8.4)
Somatic illness low 1
high 2.0(1.1–3.8)
Ache/fatigue low 1
high 2.1(1.1–4.2)
Consulters no 1
yes 12.3(6.3–23.9)
Age (continuous) 0.96 (0.94–0.99)
Sex female 1
male 0.9 (0.5–1.7)BMC Medicine 2005, 3:8 http://www.biomedcentral.com/1741-7015/3/8
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and the sample groups or between the population sam-
ples from 1988 and 1995. Also, the proportions of those
reporting symptoms explicable in terms of an organic dis-
ease have been shown to be insignificant [13]. Thus, the
FGID subjects and the symptom-free subjects would seem
to be representative.
The validity of the research tool is a potential source of
bias. However, for symptom reporting, only well-vali-
dated questionnaires were used. Both the ASQ and the
CSQ have been adequately validated [28-30]. The psycho-
logical illness factor identified in this study embraces
symptoms of both "neurotic" and "personality" dimen-
sions, listed in Table 3, and the outcome seems plausible.
The questionnaire used to assess medical knowledge was
simple and straightforward, with kappa values per ques-
tion 1 = 0.70, 2 = 0.89, 3 = 0.47, 4 = 0.78, 5 = 0.80, 6 =
0.70 when repeated within a week, considered acceptable
for all with some reservation in the 0.47 case [53].
The definitions of dyspepsia and IBS used in this study
were those used in the original study from 1988 [31],
when the Rome II criteria [11] were unavailable. We opted
to retain our original study definitions despite ongoing
changes.
Our definition of dyspepsia was more restricted in terms
of symptoms than the Rome II definition, but wider in
terms of abdominal location, as not only epigastric but
also mid abdominal symptoms were included. The IBS
definition used was in accordance with the Rome II crite-
ria [22]. Consequently, we consider the overall prevalence
of FGID in this study and the concordance on an individ-
ual level to be applicable within today's definitions [11].
Subjects with FGID were on average younger than con-
trols without FGID, which may be expected as the preva-
lence of dyspepsia and IBS is generally higher in younger
age groups [32]. This study was not a case control study,
however, but a study of all subjects with FGID and SSF
within the cohort. Any differences caused by this grouping
strategy were controlled for in the analysis by gender- and
age-adjusted logistic regression. There was a particular
association between FGID and psychological illness,
although "fibromyalgia-like" symptoms (ache and
fatigue) [49] and other somatic complaints were also
common. Previous outpatient studies have shown that
IBS is associated with psychiatric illnesses such as depres-
sion [34], dysthymia [35] and anxiety [36], and similar
findings are reported for dyspepsia [50,51]. Greater men-
tal pathology has been reported for consulters, i.e.
patients, than non-consulters with IBS [44,45,52], but this
has not been demonstrated convincingly in dyspepsia
subjects [53].
Healthcare seeking behaviour is complex and until now it
has been studied largely in patient samples. Nyrén et al.
found that patients with non-ulcer dyspepsia had an
excessive need for sick leave compared with ulcer patients,
but that the predominant reason for leave was related to
musculoskeletal rather than abdominal symptoms [41].
Kettell et al. [42] found that severity of abdominal pain
and anxiety about the seriousness of their condition were
important factors in patients consulting for IBS [42].
There seem to be no differences in the use of healthcare
services or co-morbidity status between the year before
and the year after diagnosis of IBS [43,46].
Although this study was focused on total co-morbidity, in
terms of consultation, other factors associated with FGID
consultation were also considered. The total consultation
pattern for the subjects will be published elsewhere. In
essence, effective treatment of patients with FGID involves
not only addressing GI discomfort, but also considering
mental and somatic complaints such as depression and
exhaustion.
Conclusion
In the present study, psychological illness proved to be an
important co-morbidity factor among subjects with FGID,
and the severities of the two were linked. We cannot con-
clude anything about the cause of the relationship. The
presence of psychological illness was also associated with
a greater need for medical consultation. Fear of life-threat-
ening illness has been reported to be an important reason
for consultation in FGID [1], and this worry and anxiety
needs to be taken into account when attempting to man-
age FGID successfully. Somatic co-morbidity was found to
be a less important reason for consultation, although a
high proportion of subjects with FGID (77%) in our study
Table 5: Odds ratio of consulting for abdominal complaints in the 
ASQ, 1995, for psychological illness, abdominal illness, age and 
sex, for both FGID and SSF. Odds ratio (OR, with 95% 
confidence intervals (CI) of consulting for abdominal complaints 
in the ASQ for 1995 for psychological illness, abdominal illness, 
age and sex for both FGID and SSF (n = 232). Logistic regression. 
Somatic illness and ache/fatigue were excluded in the final model 
because they showed no significance in the prior step.
Variable OR (CI)
Psychological illness low 1
High 2.2 (1.2–4.0)
Abdominal illness low 1
High 2.0 (1.1–3.8)
Age (continuous) 1.0 (0.99–1.0)
Sex female 1
Male 0.7 (0.40–1.3)BMC Medicine 2005, 3:8 http://www.biomedcentral.com/1741-7015/3/8
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were taking analgesics while only 32% used specific gas-
trointestinal medication.
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